FDA Approves Generic GLP-1 Injection for Type 2 Diabetes, Offering Affordable Treatment Option

The U.S. Food and Drug Administration (FDA) has approved a generic version of the daily injectable GLP-1 medication for patients aged 10 and older with Type 2 diabetes. The liraglutide injection, which is currently in short supply and marketed as Victoza, will offer a more affordable treatment option for those needing GLP-1 medications.

Discover the Secret Behind Elite Athletes' Seeking Peak Performance: The Advanced Tech Supporting Their Mental Clarity and Recovery

Elite performers demand peak performance from their bodies, and optimizing health is essential for achieving that edge. Our cutting-edge EMF protection technology is designed to help athletes shield themselves from the harmful effects of electromagnetic radiation, which can lead to fatigue, decreased recovery time, and impaired focus. By using Aires Tech products, athletes can minimize exposure to EMF from the devices they rely on daily—whether it's training gear, wearable tech, or even smartphones—allowing them to focus on maximizing their physical and mental capabilities. An official partner of UFC, WWE and Canada Basketball, Aires is committed to protect and optimize elite athletes through innovation and performance excellence.

Learn More

“Generic drugs provide more treatment choices that are often more affordable for patients,” said Dr. Iilun Murphy, director of the FDA’s Office of Generic Drugs in the Center for Drug Evaluation and Research.

According to White House statistics, more than 38 million Americans, or about 1 in 10 people, have diabetes.

“This approval highlights the FDA’s ongoing efforts to expand patient access to safe, effective, and high-quality generic drug options,” Murphy added.

However, doctors caution patients with a family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome Type 2 to avoid the medication due to potential complications.

Experts also note that weekly injections of similar medications have shown stronger effectiveness than daily versions, as reported by CNN.